Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
IT0004147952
Tue, 28.03.2023
Newron Pharmaceuticals S.p.A.
Newron presents six-month interim data from the first 100 patients randomized in study 014/015 at the 31st European Congress of Psychiatry
Study 014/015 is a Phase II trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia (TRS)
Full data suggest a new strategy for the management of TRS patients in the fu [ … ]
Tue, 28.03.2023
Newron Pharmaceuticals S.p.A.
Newron presents six-month interim data from the first 100 patients randomized in study 014/015 at the 31st European Congress of Psychiatry
Study 014/015 is a Phase II trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia (TRS)
Full data suggest a new strategy for the management of TRS patients in the fu [ … ]
Mon, 20.03.2023
Newron Pharmaceuticals S.p.A.
Newron reports compelling topline results from all patients in Study 014, its Phase II clinical trial evaluating evenamide as add-on therapy for treatment-resistant schizophrenia
Results from all 161 patients at the 6-week primary endpoint show a statistically significant improvement over baseline in all efficacy measures
Results consistent wi [ … ]
Mon, 20.03.2023
Newron Pharmaceuticals S.p.A.
Newron reports compelling topline results from all patients in Study 014, its Phase II clinical trial evaluating evenamide as add-on therapy for treatment-resistant schizophrenia
Results from all 161 patients at the 6-week primary endpoint show a statistically significant improvement over baseline in all efficacy measures
Results consistent wi [ … ]
Fri, 17.03.2023
Newron Pharmaceuticals S.p.A.
Newron to present at the 31st European Congress of Psychiatry
Presentation will include full data from the six-month interim timepoint from the cohort of the first 100 patients randomized in study 014/015, a Phase II trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia
Milan, Italy, March 17, 2023, 7am [ … ]
Fri, 17.03.2023
Newron Pharmaceuticals S.p.A.
Newron to present at the 31st European Congress of Psychiatry
Presentation will include full data from the six-month interim timepoint from the cohort of the first 100 patients randomized in study 014/015, a Phase II trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia
Milan, Italy, March 17, 2023, 7am [ … ]
Tue, 14.03.2023
Newron Pharmaceuticals S.p.A.
Newron announces 2022 financial results and provides outlook for 2023
Milan, Italy, March 14, 2023, 7 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its fina [ … ]
Tue, 14.03.2023
Newron Pharmaceuticals S.p.A.
Newron announces 2022 financial results and provides outlook for 2023
Milan, Italy, March 14, 2023, 7 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its fina [ … ]
Thu, 16.02.2023
Newron Pharmaceuticals S.p.A.
Newron reports striking one-year interim efficacy results from its Phase II clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia
Highly compelling, statistically significant, clinically meaningful improvement in assessments of symptoms of psychosis, disease severity and global evaluation at [ … ]
Thu, 16.02.2023
Newron Pharmaceuticals S.p.A.
Newron reports striking one-year interim efficacy results from its Phase II clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia
Highly compelling, statistically significant, clinically meaningful improvement in assessments of symptoms of psychosis, disease severity and global evaluation at [ … ]